Newsroom Bayer

February
21,
2024
| 14:00 PM Europe/Amsterdam

Bayer driving progress in Radiology through innovation in research and Radiology AI

Not intended for U.S. and UK Media - 2024 European Congress of Radiology:

New research and clinical development data on investigational compound gadoquatrane, Bayer’s novel investigational MRI contrast agent in late-stage clinical development, as well as its approved MR contrast agent gadobutrol to be presented at ECR
February
20,
2024
| 08:30 AM Europe/Amsterdam
Anti-alpha2 antiplasmin antibody is being studied in patients with deep vein thrombosis to assess its potential as a thrombolytic / Anti-alpha2 antiplasmin antibody might also provide potential treatment options in indications of high medical
February
19,
2024
| 17:23 PM Europe/Amsterdam
Leverkusen, February 19, 2024 – Bayer AG plans to amend its dividend policy to pay out the legally required minimum for three years. This follows a review of the company’s capital allocation priorities to reduce debt. This change would result in a
February
13,
2024
| 08:30 AM Europe/Amsterdam
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms / GenePHIT is a clinical trial to evaluate the safety and efficacy of the
February
06,
2024
| 08:29 AM Europe/Amsterdam
VVD-130850 is an investigational oral small molecule inhibitor of STAT3 transcription factor developed for treatment of advanced solid and hematologic tumors as a single agent and in combination with checkpoint inhibitors / Innovative clinical
January
24,
2024
| 08:29 AM Europe/Amsterdam
Study data are now under review by the regulatory body in China / Submission refers to treatment of wet age-related macular degeneration based on the phase III study PULSAR, that demonstrated unprecedented durability results with treatment intervals
January
23,
2024
| 15:04 PM Europe/Amsterdam
First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021 / Primary photoreceptor diseases affect the structure and function of the
January
22,
2024
| 14:29 PM Europe/Amsterdam
Berlin, January 22, 2024 – Bayer today announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and
January
18,
2024
| 08:29 AM Europe/Amsterdam

New Eylea™ 8 mg approved in Japan

Not intended for U.S. and UK Media

Japanese Ministry of Health, Labour and Welfare (MHLW) approved new Eylea 8 mg (aflibercept 8 mg) for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) based on positive results from clinical trials PULSAR
January
17,
2024
| 19:04 PM Europe/Amsterdam

Bayer aims to sustainably improve performance with new organization

Board of Management and employee representatives agree on future direction

New operating model aims to reduce hierarchies, eliminate bureaucracy and accelerate decision-making processes / Joint declaration: No compulsory redundancies until the end of 2026, future concept for Bayer in Germany confirmed
January
17,
2024
| 14:29 PM Europe/Amsterdam
Bayer continues to focus on advancing prostate cancer care, presenting additional data on darolutamide from the ARASENS trial and radium-223 dichloride from the REASSURE trial

Sign up for our Newsletter

We will keep you informed about the latest news.